NeuroPace Inc. logo

NeuroPace Inc. (NPCE)

Market Closed
17 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
16. 08
-0.39
-2.3679%
$
540.04M Market Cap
- P/E Ratio
- Div Yield
89,100 Volume
-1.16 Eps
$ 16.47
Previous Close
Add Transaction
Day Range
15.85 16.49
Year Range
7.56 19.6
Want to track NPCE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NPCE closed today lower at $16.08, a decrease of -2.3679% from yesterday's close, completing a monthly increase of 1.1957% or $0.19. Over the past 12 months, NPCE stock gained 3.143%.
NPCE is not paying dividends to its shareholders.
The last earnings report, released on May 12, 2026, exceeded the consensus estimates by 0.2%. On average, the company has surpassed earnings expectations by 0.104%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

NPCE Chart

People also search for

Nurix Therapeutics Inc.
$ 23.12
+0.2167%
Urogen Pharma Ltd.
$ 40.23
+0.575%
GH Research plc
$ 28.71
-1.4418%
Eventide Healthcare & Life Sciences Fund Class A Shares
$ 55.12
+1.9419%
Maze Therapeutics Inc.
$ 28.12
+3.5156%
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and investments may pressure near-term profits.

Zacks | 3 days ago
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade

The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks | 1 month ago
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?

NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?

NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 month ago

NeuroPace Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
LJB
Laura J. Bornheimer GWN SECURITIES Inc.
22,644 $297,769 $366,932.43 $69,163.43 23.23%
Anthony Scaramucci
Anthony Scaramucci SkyBridge Capital II LLC
692,000 $8.22M $11.18M $2.96M 36.02%
Point72 Asset Management LP
Point72 Asset Management LP Point72 Asset Management LP
152,025 $2.06M $2.46M $403,477.98 19.63%
Joseph Castro
Joseph Castro Nuveen LLC
89,287 $1.28M $1.45M $170,545.85 13.36%
SE
Sima Elimelech Activest Wealth Management
125 $1,643.75 $2,058.75 $415 25.25%

NeuroPace Inc. (NPCE) FAQ

What is the stock price today?

The current price is $16.08.

On which exchange is it traded?

NeuroPace Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is NPCE.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 540.04M.

Has NeuroPace Inc. ever had a stock split?

No, there has never been a stock split.

NeuroPace Inc. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Joel D. Becker CEO
NASDAQ (NMS) Exchange
641288105 CUSIP
US Country
220 Employees
- Last Dividend
- Last Split
22 Apr 2021 IPO Date

Overview

NeuroPace, Inc. is a medical device company based in the United States, specifically headquartered in Mountain View, California. Founded in 1997, the company focuses on developing innovative solutions for patients with medically refractory focal epilepsy. Its flagship product, the RNS System, represents a significant advancement in brain-responsive neuromodulation technology. This system offers personalized, real-time treatment by targeting the seizure source directly within the brain. Beyond its primary mission to improve the quality of life for individuals suffering from focal epilepsy, NeuroPace, Inc. takes pride in its contributions to the broader medical and scientific communities through continuous brain activity data collection. This data not only aids in the personal monitoring of patients by clinicians but also supports remote patient management, enhancing care delivery and patient outcomes.

Products and Services

The RNS System is NeuroPace, Inc.'s premier solution, comprising several components and services designed to support the needs of both patients and healthcare providers:

  • RNS Neurostimulator: At the core of the RNS System, the neurostimulator is a brain-responsive device that analyzes brain activity to detect abnormal patterns and delivers subtle electrical pulses to normalize brain activity before seizures can occur.
  • Cortical Strip and Depth Leads: These leads are connected to the RNS Neurostimulator and placed at strategic locations within the brain to record electrical activity and deliver stimulation directly to the seizure source.
  • Patient Remote Monitor: Enables patients to transmit data collected by the RNS System to their healthcare providers, facilitating both in-person and remote monitoring of their condition. This tool is crucial for the ongoing assessment of treatment efficacy and the adjustment of therapy parameters as necessary.
  • Implantable and Non-Implantable Accessories: To support the functionality of the RNS System, NeuroPace, Inc. offers a range of additional accessories necessary for the initial implant procedure and for ongoing maintenance or replacement procedures.

These products and services are delivered to hospital facilities across the United States, emphasizing the company's commitment to providing comprehensive solutions for the treatment and management of medically refractory focal epilepsy. Through its innovative offerings, NeuroPace, Inc. seeks to redefine the standard of care for epilepsy patients, offering them hope for a better quality of life.

Contact Information

Address: 455 North Bernardo Avenue
Phone: 650 237 2700